Arrowgrass Capital Partners (US)’s Alexion Pharmaceuticals ALXN Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$5.41M	Hold	50,000	–	–	1.42%	27
2019 Q3	$4.9M	Hold	50,000	–	–	0.36%	78
2019 Q2	$6.55M	Hold	50,000	–	–	0.16%	168
2019 Q1	$6.76M	Buy	+50,000	New	+$6.22M	0.2%	147
2014 Q4	–	Sell	-32,000	Closed	-$5.31M	–	494
2014 Q3	$5.31M	Buy	+32,000	New	+$5.26M	0.13%	110

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s ALXN Position: Q4 2019 in Review

Arrowgrass Capital Partners (US) reduced its Alexion Pharmaceuticals (ALXN) stake by 20% in Q4 2019, selling an estimated $480K and leaving 17,461 shares worth $1.89M. The position accounts for 0.5% of the portfolio, ranked #46.

Arrowgrass Capital Partners (US) first reported a position in ALXN in Q1 2015 and has held it in 6 quarters since. The position peaked at $7.23M in Q2 2015. 667 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

Arrowgrass Capital Partners (US) held 17,461 shares of Alexion Pharmaceuticals worth $1.89M as of Q4 2019.
Arrowgrass Capital Partners (US) sold 4,492 Alexion Pharmaceuticals shares in Q4 2019, an estimated $480K.
Alexion Pharmaceuticals made up 0.5% of Arrowgrass Capital Partners (US)'s portfolio in Q4 2019, its #46 holding.
Arrowgrass Capital Partners (US) first reported a position in Alexion Pharmaceuticals in Q1 2015 and has held it in 6 quarters since.
Arrowgrass Capital Partners (US)'s Alexion Pharmaceuticals position peaked at $7.23M in Q2 2015.
667 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2019, filed 14 Feb 2020.